What is Seres Therapeutics, Inc.'s Market Cap?

Seres Therapeutics, Inc.'s Market Cap is $20.8M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Price / Sales?

Seres Therapeutics, Inc.'s Price / Sales is 11.0×, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Revenue (TTM)?

Seres Therapeutics, Inc.'s Revenue (TTM) is $1.9M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Net Income (TTM)?

Seres Therapeutics, Inc.'s Net Income (TTM) is -$22.5M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s EBITDA?

Seres Therapeutics, Inc.'s EBITDA is -$80.6M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Diluted EPS (TTM)?

Seres Therapeutics, Inc.'s Diluted EPS (TTM) is -2.26, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s EBITDA Margin?

Seres Therapeutics, Inc.'s EBITDA Margin is -4279.6%, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / PHARMACEUTICAL PREPARATIONS

Seres Therapeutics, Inc.

XNAS · usd

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG0099X6868

2.09▼ 0.04 (-1.88%)

As of 2026-10-23

Price / Volume

Valuation

Market Cap
Enterprise Value: —
Trailing P/E: —
Price / Sales
EV / Revenue: —
EV / EBITDA: —

Financial Highlights

Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt: —

Trading Information

Previous Close: 2.13
Day's Range: 2.00 – 2.17
52-Week Range: 2.00 – 29.98
Volume: 69.7K
Avg Volume: 71.6K

Share Statistics

Shares Outstanding
Employees: 66
Exchange: XNAS
Listed: 2015-06-26

Share count as of August 3, 2026

Seres Therapeutics, Inc. (MCRB) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Seres Therapeutics, Inc. (MCRB)

What is Seres Therapeutics, Inc.'s Market Cap?: Seres Therapeutics, Inc.'s Market Cap is $20.8M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Price / Sales?: Seres Therapeutics, Inc.'s Price / Sales is 11.0×, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Revenue (TTM)?: Seres Therapeutics, Inc.'s Revenue (TTM) is $1.9M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Net Income (TTM)?: Seres Therapeutics, Inc.'s Net Income (TTM) is -$22.5M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s EBITDA?: Seres Therapeutics, Inc.'s EBITDA is -$80.6M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Diluted EPS (TTM)?: Seres Therapeutics, Inc.'s Diluted EPS (TTM) is -2.26, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s EBITDA Margin?: Seres Therapeutics, Inc.'s EBITDA Margin is -4279.6%, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · MCRBAs-filed SEC (XBRL) data